FDA Oncology Announcements

RET inhibitor × Thoracic × Clear all

5 Announcements

FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

Trial: ARROW
Drug: Gavreto (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Other solid neoplasm

FDA approves pralsetinib for lung cancer with RET gene fusions

Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves pralsetinib for lung cancer with RET gene fusions

Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Thoracic